Clinical markers (body mass index, percentage of body fat, waist circumference, systolic and diastolic blood pressures) and laboratory parameters (glucose, insulin, total cholesterol and fractions, triglycerides, homeostasis assessment of insulin resistance index [HOMA-IR], leptin, tumor necrosis fator-α [TNF-α], soluble TNF receptors [sTNFR1 and sTNFR2], soluble Tumor necrosis factor-Related Apoptosis-Inducing Ligand [sTRAIL]) were evaluated. This evidence concerns the gene INS and Insulin resistance.